Florbetaben (18F) receives orphan drug designation to diagnose ATTR
The European Union has granted Orphan Drug Designation to the radioactive tracer florbetaben (18F) for the diagnosis of ATTR-CM.
News
-
-
Cardiac MRI can identify biomarkers in asymptomatic ATTR mutation carriers
Cardiac magnetic resonance imaging is valuable even in patients with amyloidosis without obvious heart disease.
-
New study examines how wild-type ATTR-CM differs in men and women
There appear to be key differences between men and women regarding prevalence, prognosis, and survival in wild-type ATTR-CM.
-
New tool to identify cardiac amyloidosis risk in African American veterans
Researchers developed a new dashboard to identify African American veterans at risk of cardiac amyloidosis, including hereditary ATTR-CM.
-
Nearly 1 in 3 older adults with certain ‘red flag’ conditions may have ATTR-CM
Nearly 1 in 3 older adults with heart issues or carpal tunnel may have undiagnosed ATTR-CM, a new study shows.
-
Gut bacteria may play a role in hereditary ATTR-CM
A recent study suggests that the gut microbiome might affect how hereditary transthyretin amyloid cardiomyopathy develops.
-
Vutrisiran slows disease and reduces hospitalizations in ATTR-CM, study finds
A new study building on the results of the HELIOS-B trial found further evidence of vutrisiran’s beneficial effects for people with ATTR-CM.
-
Amyloid deposits in the prostate could help diagnose ATTR-CM
Examining prostate tissue to check for amyloid deposits may help identify cases of transthyretin amyloid cardiomyopathy (ATTR-CM).
-
Patients with ATTR face financial distress comparable to patients with cancer
Financial distress remains a significant problem in cases of rare diseases such as ATTR-CM.
-
ATTR-CM cardiac muscle produces less force than expected, study finds
Cardiac muscle (myocardium) in patients with ATTR-CM appears to have reduced contractile force compared to healthy cardiac muscle.
